Management of Iron Overload in Infants and Toddlers With Diamond-Blackfan Anemia Syndrome: A French-Italian Study

Francesca Torchio1,2, Baptiste Lecalvez3, Emanuela Garelli1

  • 1Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy.

Insights

Early iron chelation therapy is safe and effective for Diamond-Blackfan Anemia Syndrome (DBAS) patients under three years old. This treatment significantly reduces iron levels, preventing cardiac overload in young children with transfusion-dependent anemia.

Area of Science:

  • Hematology
  • Pediatric Medicine
  • Pharmacology

Background:

  • Diamond-Blackfan Anemia Syndrome (DBAS) necessitates chronic transfusions, leading to early iron overload.
  • Limited data exist on iron chelation efficacy and safety in DBAS patients younger than three years.
  • Iron overload in infancy can cause severe complications, including cardiac dysfunction.

Purpose of the Study:

  • To evaluate the feasibility, tolerability, and effectiveness of early iron chelation in transfusion-dependent DBAS patients under three years of age.
  • To assess the impact of chelation on serum ferritin levels and iron concentration.
  • To determine the incidence of cardiac iron overload in this pediatric population.

Main Methods:

  • Retrospective, multicenter study utilizing French and Italian national DBAS registries.
  • Inclusion of 167 transfused DBAS patients, with 64 initiating chelation before age three.
  • Analysis of chelation agents (Deferasirox, Deferoxamine), serum ferritin, liver iron concentration, and cardiac magnetic resonance findings.

Main Results:

  • Chelation initiated at a median age of 18 months in 64 patients (38%).
  • Significant annual reduction in serum ferritin levels (-11%; p < 0.001) with chelation.
  • No myocardial iron overload detected in 22 patients; 45% showed severe liver iron overload initially.

Conclusions:

  • Early iron chelation is feasible, tolerable, and effective in preventing cardiac iron overload in young DBAS patients.
  • Findings support age-specific chelation strategies for infants and toddlers with transfusion-dependent anemias.
  • Real-world data confirm the benefits of early intervention in managing iron overload in pediatric anemia.

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...